Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis
- 8 August 2022
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (10) , 1494-1502
Abstract
Purpose To assess the value of quantitative analysis of tumor burden on baseline MRI for prediction of survival in patients with neuroendocrine tumor liver metastases (NELM) undergoing intra-arterial therapies. Materials and Methods This retrospective single-center analysis included 122 patients with NELM who received conventional (n = 74) or drug-eluting beads, (n = 20) chemoembolization and radioembolization (n = 28) from 2000 to 2014. Overall tumor diameter (1D) and area (2D) of up to 3 largest liver lesions were measured on baseline arterially contrast enhanced MR images. Three-dimensional quantitative analysis was performed using the qEASL tool (IntelliSpace Portal Version 8, Philips) to calculate enhancing tumor burden (the ratio between enhancing tumor volume and total liver volume). Based on Q-statistics, patients were stratified into low tumor burden (TB) or high TB. Results The survival curves were significantly separated between low TB and high TB groups for 1D (p < 0.001), 2D (p < 0.001) and enhancing TB (p = 0.008) measurements, with, respectively, 2.7, 2.6 and 2.2 times longer median overall survival (MOS) in the low TB group (p < 0.001, p < 0.001 and p = 0.008). Multivariate analysis showed that 1D, 2D, and enhancing TB were independent prognostic factors for MOS, with respective hazard ratios of 0.4 (95%CI: 0.2–0.6, p < 0.001), 0.4 (95%CI: 0.3–0.7, p < 0.001) and 0.5 (95%CI: 0.3–0.8, p = 0.003). Conclusion The overall tumor diameter, overall tumor area, and enhancing tumor burden are strong prognostic factors of overall survival in patients with neuroendocrine tumor liver metastases undergoing intra-arterial therapies.Keywords
Funding Information
- National Institutes of Health (R01 CA160771)
- Rolf W. Günther Foundation for Radiological Science
This publication has 28 references indexed in Scilit:
- Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image AnalysisRadiology, 2014
- Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinomaEuropean Journal of Radiology, 2014
- Factors Affecting Periprocedural Morbidity and Mortality and Long-term Patient Survival after Arterial Embolization of Hepatic Neuroendocrine MetastasesJournal of Vascular and Interventional Radiology, 2014
- Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine MetastasesJournal of Vascular and Interventional Radiology, 2013
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown PrimaryNeuroendocrinology, 2012
- Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular CarcinomaJAMA, 2010
- Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic diseaseBritish Journal of Surgery, 2009
- Functional MRI Evaluation of Tumor Response in Patients with Neuroendocrine Hepatic Metastasis Treated with Transcatheter Arterial ChemoembolizationAmerican Journal of Roentgenology, 2008
- Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumorsCancer, 2005
- The carcinoid syndrome: palliation by hepatic artery embolizationAmerican Journal of Roentgenology, 1986